Switching Breast Cancer Patients with Progressive Bone Metastases to Third-Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone Pain
Authors:
- Hongyan DuHDHongyan Du
- Mark ClemonsMCMark Clemons
- David EtonDEDavid Eton
- George DranitsarisGDGeorge Dranitsaris
- Christine SimmonsCSChristine Simmons
- Wei OoiWOWei Ooi
- David CellaDCDavid Cella
- 1 August 2009
- journal article
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 38 (2) , 244-257
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate TherapyJournal of Clinical Oncology, 2006
- Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2005
- Assessment of therapeutic response in patients with metastatic bone diseaseThe Lancet Oncology, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994
- PamidronateAnnals of Pharmacotherapy, 1992
- Bone metastasis in breast cancerAnti-Cancer Drugs, 1992
- Structure-activity relationships of various bisphosphonatesCalcified Tissue International, 1983